Target intelligence / Profile preview

Alpha-neurotoxin (null)

Target
null
Molecular classification
Toxin, Three-finger toxin (3FTx) family, Snake venom protein, Other
01

Overview

Postsynaptic neurotoxins, commonly referred to as alpha-neurotoxins, are a class of snake venom proteins that bind with high affinity to postsynaptic nicotinic acetylcholine receptors on skeletal muscle at the neuromuscular junction, competitively inhibiting acetylcholine binding[4][5][6][7]. This blockade disrupts normal synaptic transmission, leading to paralysis, which can be fatal if respiratory muscles are affected. Alpha-neurotoxins fall into the 'three-finger toxin' (3FTx) protein superfamily and are further classified into short-chain and long-chain subtypes based on their amino acid length and disulfide bond configuration[4]. They are used extensively as probes in neuroscience to study the structure and function of acetylcholine receptors, but are not themselves therapeutic targets—rather, they are the active agents in venom toxicity for which antivenoms are developed.

Other names
Alpha-neurotoxinPostsynaptic alpha-neurotoxinSnake postsynaptic toxinα-bungarotoxin (as a prototypical member)Long-chain alpha-neurotoxinShort-chain alpha-neurotoxin
02

Mechanism of action

Competitive antagonism of nicotinic acetylcholine receptors (nAChRs) at postsynaptic membranes, blocking acetylcholine binding and preventing synaptic transmission[4][5][6]

03

Biological functions

Inhibition of nicotinic acetylcholine receptorsBlockade of synaptic transmission at neuromuscular junctionsInducing muscle paralysisOther
04

Disease associations

Neurotoxicity (paralysis, potentially fatal envenomation)Tool compound in neurobiology researchOther
05

Safety considerations

High toxicity/paralysis risk in envenomationDifficulty reversing established paralysis with standard therapeutics (requires antivenom or supportive care)
06

Interacting drugs

No clinically approved drugs targeting the toxin itself, but some antivenoms neutralize it
07

Biomarkers

None established for patient selection; binding assays with labeled α-bungarotoxin are used in research

Beyond the preview

Go deeper on Alpha-neurotoxin (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-neurotoxin (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call